201 related articles for article (PubMed ID: 12904177)
21. Expression of the cell-cycle regulatory proteins (pRb, cyclin D1, p16INK4A and cdk4) in human endometrial cancer: correlation with clinicopathological features.
Semczuk A; Miturski R; Skomra D; Jakowicki JA
Arch Gynecol Obstet; 2004 Jan; 269(2):104-10. PubMed ID: 14648178
[TBL] [Abstract][Full Text] [Related]
22. Several noncontiguous domains of CDK4 are involved in binding to the P16 tumor suppressor protein.
Ceha HM; Nasser I; Medema RH; Slebos RJ
Biochem Biophys Res Commun; 1998 Aug; 249(2):550-5. PubMed ID: 9712735
[TBL] [Abstract][Full Text] [Related]
23. Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds.
Flores JF; Pollock PM; Walker GJ; Glendening JM; Lin AH; Palmer JM; Walters MK; Hayward NK; Fountain JW
Oncogene; 1997 Dec; 15(24):2999-3005. PubMed ID: 9416844
[TBL] [Abstract][Full Text] [Related]
24. Characterization of the abnormal pancreatic development, reduced growth and infertility in Cdk4 mutant mice.
Mettus RV; Rane SG
Oncogene; 2003 Nov; 22(52):8413-21. PubMed ID: 14627982
[TBL] [Abstract][Full Text] [Related]
25. Complete scanning of the CDK4 gene by denaturing gradient gel electrophoresis: a novel missense mutation but low overall frequency of mutations in sporadic metastatic malignant melanoma.
Guldberg P; Kirkin AF; Gronbaek K; thor Straten P; Ahrenkiel V; Zeuthen J
Int J Cancer; 1997 Sep; 72(5):780-3. PubMed ID: 9311594
[TBL] [Abstract][Full Text] [Related]
26. Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene.
Tsao H; Benoit E; Sober AJ; Thiele C; Haluska FG
Cancer Res; 1998 Jan; 58(1):109-13. PubMed ID: 9426066
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical analysis of the D-type cyclin-dependent kinases Cdk4 and Cdk6, using a series of monoclonal antibodies.
Lukas C; Jensen SK; Bartkova J; Lukas J; Bartek J
Hybridoma; 1999 Jun; 18(3):225-34. PubMed ID: 10475236
[TBL] [Abstract][Full Text] [Related]
28. A single nucleotide polymorphism in the 3'untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare.
Kumar R; Smeds J; Berggren P; Straume O; Rozell BL; Akslen LA; Hemminki K
Int J Cancer; 2001 Nov; 95(6):388-93. PubMed ID: 11668523
[TBL] [Abstract][Full Text] [Related]
29. Cyclin-dependent kinase (cdk6) and p16 in pancreatic endocrine neoplasms.
Tomita T
Pathology; 2004 Dec; 36(6):566-70. PubMed ID: 15841692
[TBL] [Abstract][Full Text] [Related]
30. Cyclin-dependent kinase 4 (CDK4) expression in pancreatic endocrine tumors.
Lindberg D; Hessman O; Akerström G; Westin G
Neuroendocrinology; 2007; 86(2):112-8. PubMed ID: 17664862
[TBL] [Abstract][Full Text] [Related]
31. Lack of p19INK4d in human testicular germ-cell tumours contrasts with high expression during normal spermatogenesis.
Bartkova J; Thullberg M; Rajpert-De Meyts E; Skakkebaek NE; Bartek J
Oncogene; 2000 Aug; 19(36):4146-50. PubMed ID: 10962575
[TBL] [Abstract][Full Text] [Related]
32. Invasive melanoma in Cdk4-targeted mice.
Sotillo R; García JF; Ortega S; Martin J; Dubus P; Barbacid M; Malumbres M
Proc Natl Acad Sci U S A; 2001 Nov; 98(23):13312-7. PubMed ID: 11606789
[TBL] [Abstract][Full Text] [Related]
33. Cyclin D1 overexpression in invasive breast cancers: correlation with cyclin-dependent kinase 4 and oestrogen receptor overexpression, and lack of correlation with mitotic activity.
Takano Y; Takenaka H; Kato Y; Masuda M; Mikami T; Saegusa M; Okayasu I
J Cancer Res Clin Oncol; 1999; 125(8-9):505-12. PubMed ID: 10480344
[TBL] [Abstract][Full Text] [Related]
34. Driving the cell cycle to cancer.
Malumbres M; Hunt SL; Sotillo R; Martín J; Odajima J; Martín A; Dubus P; Ortega S; Barbacid M
Adv Exp Med Biol; 2003; 532():1-11. PubMed ID: 12908544
[TBL] [Abstract][Full Text] [Related]
35. Deregulation of anti-Mullerian hormone/BMP and transforming growth factor-beta pathways in Leydig cell lesions developed in male heterozygous multiple endocrine neoplasia type 1 mutant mice.
Hussein N; Lu J; Casse H; Fontanière S; Morera AM; Guittot SM; Calender A; Di Clemente N; Zhang CX
Endocr Relat Cancer; 2008 Mar; 15(1):217-27. PubMed ID: 18310289
[TBL] [Abstract][Full Text] [Related]
36. No evidence of a role for activating CDK2 mutations in melanoma.
Walker G; Hayward N
Melanoma Res; 2001 Aug; 11(4):343-8. PubMed ID: 11479422
[TBL] [Abstract][Full Text] [Related]
37. Leydig-cell tumour in children: variable clinical presentation, diagnostic features, follow-up and genetic analysis of four cases.
Petkovic V; Salemi S; Vassella E; Karamitopoulou-Diamantis E; Meinhardt UJ; Flück CE; Mullis PE
Horm Res; 2007; 67(2):89-95. PubMed ID: 17047343
[TBL] [Abstract][Full Text] [Related]
38. CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons.
Wei G; Lonardo F; Ueda T; Kim T; Huvos AG; Healey JH; Ladanyi M
Int J Cancer; 1999 Jan; 80(2):199-204. PubMed ID: 9935200
[TBL] [Abstract][Full Text] [Related]
39. CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas.
Holland EA; Schmid H; Kefford RF; Mann GJ
Genes Chromosomes Cancer; 1999 Aug; 25(4):339-48. PubMed ID: 10398427
[TBL] [Abstract][Full Text] [Related]
40. Mutation testing in melanoma families: INK4A, CDK4 and INK4D.
Newton Bishop JA; Harland M; Bennett DC; Bataille V; Goldstein AM; Tucker MA; Ponder BA; Cuzick J; Selby P; Bishop DT
Br J Cancer; 1999 Apr; 80(1-2):295-300. PubMed ID: 10390011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
